1. Cytomegalovirus (CMV) Infection and Disease Incidence and Risk Factors Across Diverse Hematopoietic Cell Transplantation (HCT) Platforms Using a Standardized Monitoring and Treatment Approach: A Comprehensive Evaluation From a Single Institution 
Rachel Marchalik, Ricardo Melendez-Munoz, Theresa Jerussi, Dimana Dimitrova, Andrea Beri, Khalid Rai, Jennifer Wilder, A. John Barrett, Minoo Battiwalla, Richard W. Childs, Courtney Fitzhugh, Daniel H. Fowler, Terry J. Fry, Ronald E. Gress, Dennis Hickstein, Matthew Hsieh, Sawa Ito, Elizabeth M. Kang, Steven Z. Pavletic, Nirali N. Shah, John F. Tisdale, Juan Gea-Banacloche, Christopher G. Kanakry, Jennifer A. Kanakry 
Biology of Blood and Marrow Transplantation 
Volume 24, Issue 3, Pages S377-S378 (March 2018)
DOI: /j.bbmt
Copyright © Terms and Conditions

2. Figure 1 Recipient, Donor, and Transplant characteristics.
Biology of Blood and Marrow Transplantation  , S377-S378DOI: ( /j.bbmt )
Copyright © Terms and Conditions

3. Figure 2
Cumulative incidence of CMV infection in the first 100 days after HCT, by donor (D) and recipient (R) CMV serostatus.
Biology of Blood and Marrow Transplantation  , S377-S378DOI: ( /j.bbmt )
Copyright © Terms and Conditions

4. Figure 3
Cumulative incidence of CMV infection in the first 100 days after HCT, by T cell manipulation strategy, with comparison using Gray's method of post-transplantation cyclophosphamide (PTCy), serotherapy (proximal ATG or alemtuzumab), ex vivo T cell depletion (TCD), and calcineurin inhibitor/mTOR inhibitor (CNI/mTOR)-based approaches.
Biology of Blood and Marrow Transplantation  , S377-S378DOI: ( /j.bbmt )
Copyright © Terms and Conditions